November 24, 2023 Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing ...
October 24, 2023 Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification ...
September 7, 2023 Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors ...
August 29, 2023 Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron ...
July 27, 2023 Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications ...
July 18, 2023 Celularity Human Placental-derived Advanced Biomaterials Demonstrate Superior Biocompatibility And Better Support Differentiated Cell Functions In Studies ...
June 29, 2023 Celularity Announces Presentation At Upcoming 7th International Conference On Orthopedics ...
June 1, 2023 Celularity Tissue Factor Gene Knockout Of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance Of Gene Editing Capability ...
May 23, 2023 Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement for Celularity’s Halal-certified Biomaterial Products Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement for Celularity’s Halal-certified Biomaterial Products
May 19, 2023 Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation ...
May 1, 2023 Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy ...
April 27, 2023 Celularity Announces Clinical Data on Human Placental-derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate CYNK-001 in Adult Patients With Relapsed Refractory And Measurable Residual Disease-positive Acute Myeloid Leukemia Today we announced the appointment of Paul Graves as Chief Communications Officer. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry.
April 12, 2023 Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™” ...
April 4, 2023 Celularity Announces Acceptance of Poster Presentation at 2023 Society For Biomaterials Annual Meeting ...
April 3, 2023 Celularity Receives U.S. Food and Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health ...
March 28, 2023 Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt ...
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
Letter to shareholders
Celularity Inc. Announces $3 Million Registered Direct Offering
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications
Celularity Human Placental-derived Advanced Biomaterials Demonstrate Superior Biocompatibility And Better Support Differentiated Cell Functions In Studies
Celularity Announces Presentation At Upcoming 7th International Conference On Orthopedics
Celularity Tissue Factor Gene Knockout Of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance Of Gene Editing Capability
Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement for Celularity’s Halal-certified Biomaterial Products
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation
Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy
Celularity Announces Clinical Data on Human Placental-derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate CYNK-001 in Adult Patients With Relapsed Refractory And Measurable Residual Disease-positive Acute Myeloid Leukemia
Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”
Celularity Inc. Announces $6 Million Registered Direct Offering
Celularity Announces Acceptance of Poster Presentation at 2023 Society For Biomaterials Annual Meeting
Celularity Receives U.S. Food and Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt